A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

NCT04540185 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

3600

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19
SARS (Severe Acute Respiratory Syndrome)
SARS-CoV Infection
SARS-CoV-2

Interventions

BIOLOGICAL: Biological: oral polio vaccine
BIOLOGICAL: Comparable Placebo
DRUG: NA-831
DRUG: Comparable Placebo of drug
COMBINATION_PRODUCT: Combination of oral polio vaccine and NA-831
COMBINATION_PRODUCT: Comparable Placebo of Oral Polio Vaccine and Placebo of drug

Sponsor

Biomed Industries, Inc.